Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer

NCT01773785 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
30
Enrollment
INDUSTRY
Sponsor class

Stopped The study completed the first phase and did not meet efficacy end point to enter into the randomized phase.

Conditions

Interventions

Sponsor

Spectrum Pharmaceuticals, Inc